# Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

> **NCT03672240** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asieris Pharmaceutical Technologies Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** APL-1202

## Key facts

- **NCT ID:** NCT03672240
- **Lead sponsor:** Asieris Pharmaceutical Technologies Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-30
- **Primary completion:** 2019-10-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672240, "Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03672240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*